Maladies auto-immunes du foie et grossesse (notice n° 266604)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04385cam a2200349 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112075419.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Gournay, Jérôme |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Maladies auto-immunes du foie et grossesse |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2020.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 94 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les modifications physiologiques de l’immunité au cours de la grossesse peuvent changer l’évolution des maladies auto-immunes du foie. La présence d’une maladie chronique évolutive du foie peut avoir un impact sur le déroulement de la grossesse et donc sur le développement et la croissance du fœtus. Au cours de l’hépatite auto-immune, le principal risque est la survenue d’une poussée pendant la grossesse et surtout dans les mois qui suivent l’accouchement. Le risque est plus élevé si le traitement immunosuppresseur a été diminué ou suspendu pendant la grossesse : celui-ci doit donc être maintenue. Le risque de prématurité est plus élevé. Au cours d’une grossesse chez une femme atteinte de cholangite biliaire primitive, on observe le plus souvent une stabilisation ou une amélioration des tests hépatiques. Après l’accouchement, une détérioration des tests hépatiques est observée dans 70 % des cas. Le plus souvent, il n’y a pas de progression du stade de la maladie du foie. Le traitement par acide ursodésoxycholique (AUDC) doit être maintenu pendant toute la durée de la grossesse et l’allaitement. Les données publiées chez les femmes enceintes exposées à l’AUDC sont très peu nombreuses mais aucun élément inquiétant n’a été signalé. Un prurit de novo ou une accentuation d’un prurit préexistant peut survenir environ une fois sur deux. Il y a une augmentation du risque de survenue d’interruption spontanée de la grossesse. Au cours de la grossesse chez les femmes atteintes de cholangite sclérosante primitive, les tests hépatiques restent stables dans la plupart des cas. Il y a une augmentation du risque de prématurité et de naissance par césarienne. La grossesse chez les patientes atteintes de maladie auto-immune du foie peut donc entraîner des problèmes maternels et fœtaux. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Physiological changes in immunity during pregnancy may affect the course of autoimmune liver disease. An ongoing progressive chronic liver disease may have an impact on the course of pregnancy and therefore on the development and growth of the fetus. The main risk during autoimmune hepatitis is a flare-up during pregnancy, especially in the months after delivery. The risk is higher if the immunosuppressive treatment has been reduced or suspended during pregnancy: It should therefore be continued. The risk of prematurity is higher. During pregnancy in a woman with primary biliary cholangitis, stabilization or improvement in liver tests is most often seen. After delivery, worsening liver tests can occur in 70% of cases. Usually, there is no progression from the stage of liver disease. Ursodesoxycholic acid (UDCA) treatment should be continued for the duration of pregnancy and breastfeeding. There are very few published data from pregnant women exposed to UDCA, but no worrying signal have been reported. Pruritus de novo or worsening of pre-existing pruritus can occur in 50% of cases. There is an increasing risk of spontaneous termination of pregnancy. During pregnancy in women with primary sclerosing cholangitis, liver tests remain usually stable. There is an increasing risk of prematurity and cesarean birth. Pregnancy in women with autoimmune liver disease can lead to maternal and fetal problems. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | acide ursodésoxycholique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hépatite auto-immune |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cholangite biliaire primitive |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | azathioprine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | prématurité |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cholangite sclérosante primitive grossesse |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pregnancy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | autoimmune hepatitis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ursodeoxycholic acid |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | primary biliary cholangitis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | azathioprine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | prematurity |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | primary sclerosing cholangitis |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Imbert, Astrid |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Habes, Sarah |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 27 | 5 | 2020-05-01 | p. 429-437 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2020-5-page-429?lang=fr">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2020-5-page-429?lang=fr</a> |
Pas d'exemplaire disponible.
Réseaux sociaux